A Favorable Prognosis for This Pharma Stock
Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.
Stefan Quenneville: We think Vertex Pharmaceuticals (VRTX) has a positive moat trend because its recent clinical success in cystic fibrosis positions it as a dominant player in this very attractive rare-disease market.
Currently, the company is trading at a slight discount to our fair value estimate. When I say rare disease, you may think that it's a small opportunity, whereas this is one of the most lucrative areas in the pharmaceutical industry because of the ability to charge extremely high prices for effective treatments for very serious disorders.
Stefan Quenneville, CFA does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.